Truist Financial Boosts Lantheus (NASDAQ:LNTH) Price Target to $127.00

Lantheus (NASDAQ:LNTH) had its price objective raised by analysts at Truist Financial from $120.00 to $127.00 in a research report issued on Thursday,Benzinga reports. The brokerage currently has a “buy” rating on the medical equipment provider’s stock. Truist Financial’s target price points to a potential upside of 35.12% from the company’s current price.

A number of other research firms also recently commented on LNTH. StockNews.com downgraded Lantheus from a “buy” rating to a “hold” rating in a report on Thursday, November 21st. The Goldman Sachs Group began coverage on Lantheus in a research note on Wednesday, December 18th. They set a “buy” rating and a $143.00 price target for the company. Finally, JMP Securities restated a “market outperform” rating and issued a $112.00 price objective on shares of Lantheus in a report on Tuesday, January 14th. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, Lantheus presently has a consensus rating of “Moderate Buy” and a consensus target price of $132.86.

Lantheus Stock Performance

LNTH stock opened at $93.99 on Thursday. The company has a 50 day moving average price of $89.81 and a two-hundred day moving average price of $96.78. The stock has a market capitalization of $6.53 billion, a P/E ratio of 15.71 and a beta of 0.44. Lantheus has a one year low of $56.44 and a one year high of $126.89.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings data on Thursday, February 27th. The medical equipment provider reported $1.34 EPS for the quarter, missing analysts’ consensus estimates of $1.57 by ($0.23). Lantheus had a net margin of 28.57% and a return on equity of 44.29%. Research analysts forecast that Lantheus will post 6.01 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Lantheus news, Director James H. Thrall sold 1,000 shares of the business’s stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $94.76, for a total value of $94,760.00. Following the transaction, the director now owns 33,207 shares in the company, valued at $3,146,695.32. The trade was a 2.92 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 1.50% of the stock is owned by company insiders.

Institutional Trading of Lantheus

A number of hedge funds and other institutional investors have recently modified their holdings of LNTH. Geode Capital Management LLC grew its stake in Lantheus by 2.0% during the 3rd quarter. Geode Capital Management LLC now owns 1,683,500 shares of the medical equipment provider’s stock valued at $184,798,000 after purchasing an additional 32,551 shares in the last quarter. Moloney Securities Asset Management LLC bought a new stake in shares of Lantheus in the third quarter worth $1,066,000. Massachusetts Financial Services Co. MA acquired a new stake in Lantheus in the third quarter valued at $25,955,000. Van ECK Associates Corp boosted its stake in Lantheus by 58.6% during the 3rd quarter. Van ECK Associates Corp now owns 58,472 shares of the medical equipment provider’s stock valued at $6,469,000 after acquiring an additional 21,604 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. grew its holdings in Lantheus by 47.7% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 11,684 shares of the medical equipment provider’s stock worth $1,041,000 after acquiring an additional 3,772 shares in the last quarter. 99.06% of the stock is owned by hedge funds and other institutional investors.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.